-
USPTO Launches "Patents 4 Patients": A Cancer Immunotherapy Program
July 22, 2016 -
Amgen v. Apotex – Biosimilar Applicants Must Provide 180-Day Notice Before Marketing Even if They Participate in the "Patent Dance"
July 12, 2016 -
USPTO Adds New Pilot Initiative That Could Help Move Pending Cases Through More Quickly – Combines Features of Pre-Appeal Conference & After-Final 2.0 Program
July 12, 2016 -
BRI is Permissible Standard in IPR; USPTO Decisions to Institute IPR May Not Be Appealed
June 20, 2016 -
Supreme Court Determines Federal Circuit Test for Enhanced Infringement Damages Too Rigid
June 14, 2016 -
Supreme Court Considers Standard For Enhanced Infringement Damages
March 2, 2016
How can we help you?
Contact us at the MMV IP Law office nearest to you or submit a inquiry online.